| Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial 2008 · WS 5570 · Adults with recurrent moderate major depression who had recovered after an acute episode; at least three previous episodes in five years | 900 mg | 26 weeks | 282 |
| Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial 2011 · Hypericum extract STW 3-VI group · Adults with mild to moderate depression who responded to treatment for an episode of moderate depression | 900 mg | 6 weeks | 54 |
| Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial 2002 · WS 5570 · Adult male and female outpatients with mild to moderate major depression, single or recurrent episode, meeting DSM-IV criteria | 900 mg | 6 weeks | 186 |
| The Ham D(6) is more homogenous and as sensitive as the Ham D(17) 2007 · hypericum extract · Patients with single or recurrent depression according to DSM-IV | 900 mg | 6 weeks | 186 |
| Comparison of St John's wort and imipramine for treating depression: randomised controlled trial 2000 · hypericum group · Outpatients with mild to moderate depression; age and sex not specified | 500 mg | 6 weeks | 157 |
| Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort 2001 · Ze 117 St. John's wort · Outpatients with mild to moderate depressive episodes, ICD-10 F32.0 or F32.1; age and sex not reported | 500 mg | 6 weeks | 126 |
| Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline 2005 · hypericum group · Patients with moderate depressive disorder | 612 mg | 24 weeks | 123 |
| Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298] 2006 · WS 5570 600 mg/day · Men and women aged 18–65 with a mild or moderate major depressive episode and baseline HAM-D score ≥18 | 600 mg | 6 weeks | 123 |
| Placebo controlled continuation treatment with Hypericum extract WS 5570 after recovery from a mild or moderate depressive episode 2007 · WS 5570 600 mg/day · Adults with mild to moderate major depression who had recovered with acute treatment and had a HAMD total score decrease of at least 50%. | 600 mg | 120 days | 69 |
| Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients 1994 · LI 160 group · Adults with depressive disorders treated as outpatients; age and sex not reported | 900 mg | 6 weeks | 67 |
| A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder 2005 · St John's wort group · Adults with major depressive disorder diagnosed by Structured Clinical Interview for DSM-IV; mean age 37.3 years; 57% women across the trial | 900 mg | 12 weeks | 45 |
| Placebo-controlled double-blind study examining the effectiveness of an hypericum preparation in 105 mildly depressed patients 1994 · active group · Outpatients with mild depression of short duration; age and sex not reported | 900 mg | 4 weeks | 42 |
| Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial 2001 · WS 5572 · Adults with mild to moderate major depressive disorder | 900 mg | 6 weeks | 37 |
| The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial 2010 · Hypericum perforatum · Women aged 18–45 years with prospectively diagnosed mild premenstrual syndrome | 900 mg | — | 36 |
| Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study 2006 · WS 5570 900 mg/d · Adult out-patients with moderate to severe major depression who responded to 6 weeks of acute treatment | 900 mg | 16 weeks | 33 |
| Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial 2003 · cycle A · healthy females | 600 mg | — | 17 |
| Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial 2003 · cycle B · healthy females | 900 mg | — | 17 |
| Hypericum in the treatment of seasonal affective disorders 1994 · Hypericum with bright light condition · Patients with major depression with seasonal pattern (seasonal affective disorder); age and sex not reported | 900 mg | 4 weeks | 10 |
| Hypericum in the treatment of seasonal affective disorders 1994 · Hypericum with dim light condition · Patients with major depression with seasonal pattern (seasonal affective disorder); age and sex not reported | 900 mg | 4 weeks | 10 |
| Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine 1999 · LoHyp-57 (St. John's wort extract) · Elderly out-patients with mild or moderate depressive episodes | 800 mg | 6 weeks | — |
| St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial 2002 · LI 160 (Hypericum) group · Outpatients with somatization disorder, undifferentiated somatoform disorder, or somatoform autonomic dysfunction; age and sex not reported | 600 mg | 6 weeks | — |
| Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial 2004 · St. John's wort group · Outpatients with somatization disorder, undifferentiated somatoform disorder, or somatoform autonomic dysfunction, without major depression; age and sex not reported | 600 mg | 6 weeks | — |
| Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo 2005 · Hypericum extract (HE LI 160) · Patients with major depressive disorder and reversed vegetative signs; age and sex not reported | 900 mg | 12 weeks | — |
| Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients 2005 · Hypericum LI 160 · Outpatients with mild to moderate major depression (DSM-IV); age and sex not reported | 900 mg | 4 weeks | — |
| Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial 2004 · Hypericum extract group · Outpatients with moderate depressive disorders and HAMD-17 scores of 20 to 24; adults, sex and age range not specified | 900 mg | 6 weeks | — |
| Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine 2005 · Hypericum group · Adults with acute moderate to severe major depression; age range not specified | 900 mg | 6 weeks | — |
| The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study 2006 · lower-dose Hypericum · Adults aged 25–70 with minor depressive symptoms, mild or moderately severe depressive episodes, or dysthymia | 810 mg | 6 weeks | — |
| The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study 2006 · higher-dose Hypericum · Adults aged 25–70 with minor depressive symptoms, mild or moderately severe depressive episodes, or dysthymia | 810 mg | 6 weeks | — |
| Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study 2006 · hypericum extract STW3-VI · Outpatients with moderate depression; age and sex not reported | 900 mg | 6 weeks | — |
| St. John's wort extract LI160 for the treatment of depression with atypical features - a double-blind, randomized, and placebo-controlled trial 2010 · LI160 · Patients with mild or moderate major depression and vegetative features of atypical depression; age and sex not specified | 600 mg | 8 weeks | — |
| The acute effect of Hypericum perforatum on short-term memory in healthy adults 2019 · Remotiv 500 · Healthy student adults; 33 of the 82 participants were women | 500 mg | 1 day | — |
| Hypericum treatment of mild depressions with somatic symptoms 1994 · Hypericum extract LI 160 · Patients with depression with somatic symptoms; age and sex not reported | 900 mg | 4 weeks | — |
| Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study 1994 · hypericum extract · Patients with depression (ICD-10, F 32.1); age and sex not specified | 900 mg | 4 weeks | — |
| LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients--a controlled 6-week clinical trial 1997 · LI 160 group · Mildly to moderately depressed outpatients; age and sex not stated | 900 mg | 6 weeks | — |
| St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy 1998 · Hypericum extract WS 5573 · Male and female outpatients with mild or moderate depression according to DSM-IV criteria | 900 mg | 6 weeks | — |
| St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy 1998 · Hypericum extract WS 5572 · Male and female outpatients with mild or moderate depression according to DSM-IV criteria | 900 mg | 6 weeks | — |
| Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298] 2006 · WS 5570 1200 mg/day · Men and women aged 18–65 with a mild or moderate major depressive episode and baseline HAM-D score ≥18 | 1.2 g | 6 weeks | 127 |
| Placebo controlled continuation treatment with Hypericum extract WS 5570 after recovery from a mild or moderate depressive episode 2007 · WS 5570 1200 mg/day · Adults with mild to moderate major depression who had recovered with acute treatment and had a HAMD total score decrease of at least 50%. | 1.2 g | 120 days | 68 |
| Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study 2006 · WS 5570 1800 mg/d · Adult out-patients with moderate to severe major depression who responded to 6 weeks of acute treatment | 1.8 g | 16 weeks | 38 |
| Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks 1999 · Hypericum extract · Adults with moderate depression, 66 men and 197 women; age range not reported | 1.05 g | 8 weeks | — |
| The acute effect of Hypericum perforatum on short-term memory in healthy adults 2019 · Remotiv 250 · Healthy student adults; 33 of the 82 participants were women | 250 mg | 1 day | — |
| Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10 1997 · LI 160 group · Patients with severe depressive episodes according to ICD-10; age and sex not reported | 1.8 g | 6 weeks | — |
| Effects of treatment with a commercially available St John's Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin 2007 · Movina · Adults with hypercholesterolemia taking a stable dose of simvastatin | 600 mg | 4 weeks | 24 |
| Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia 2007 · Movina · Patients with hypercholesterolemia taking a stable dose of atorvastatin | 600 mg | 4 weeks | 16 |
| A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of Hypericum perforatum L 1999 · 1 mg group · Adult outpatients with mild to moderate depression | 1 mg | 6 weeks | 119 |
| A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of Hypericum perforatum L 1999 · 0.33 mg group · Adult outpatients with mild to moderate depression | 330 mcg | 6 weeks | 115 |
| A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of Hypericum perforatum L 1999 · 0.17 mg group · Adult outpatients with mild to moderate depression | 170 mcg | 6 weeks | 114 |
| Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial 2009 · St. John's wort group · Symptomatic perimenopausal women aged 40 to 65 years experiencing at least three hot flashes per day | 2.7 g | 90 days | — |
| Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans 1997 · Multiple-dose hypericum extract · Volunteers; sex, age and health condition not reported | 1.81 g | 15 days | 50 |
| Pharmacodynamic effects of two different hypericum extracts in healthy volunteers measured by quantitative EEG 1998 · 0.5% hyperforin extract · Healthy volunteers aged 18–35 years | 900 mg | 8 days | 18 |
| Pharmacodynamic effects of two different hypericum extracts in healthy volunteers measured by quantitative EEG 1998 · 5.0% hyperforin extract · Healthy volunteers aged 18–35 years | 900 mg | 8 days | 18 |
| Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin 2001 · St John's Wort treatment · Healthy adult men | 900 mg | 2 weeks | 16 |
| Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans 2004 · St John's wort · Healthy adults, 11 men and 5 women; mean age 31 years | 900 mg | 7 days | 16 |
| St. John's Wort in patients non-responders to clopidogrel undergoing percutaneous coronary intervention: a single-center randomized open-label trial (St. John's Trial) 2013 · SJW · Patients with stable angina who were non-responders to clopidogrel after percutaneous coronary intervention | 900 mg | 2 weeks | 15 |
| Drug interaction between St John's Wort and quazepam 2004 · St John's Wort · healthy subjects; age and sex not specified | 900 mg | 2 weeks | 13 |
| St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole 2004 · St John's wort · Healthy adult men aged not reported, with CYP2C19 wild-type or variant genotypes | 900 mg | 2 weeks | 12 |
| The influence of St John's Wort on CYP2C19 activity with respect to genotype 2004 · St. John's wort · Healthy adult men, including CYP2C19 extensive and poor metabolizers | 900 mg | 2 weeks | 12 |
| Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba 2005 · St. John’s wort supplementation · Healthy elderly adults, 67 ± 5.2 years; 6 men and 6 women | 900 mg | 4 weeks | 12 |
| The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity 2011 · St. John's Wort, hyporesponsive volunteers · Adults identified as clopidogrel-hyporesponsive volunteers; age and sex not stated | 900 mg | 2 weeks | 10 |
| Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol 2007 · St. John’s wort (SJW) · Study subjects; age, sex, and health condition not specified | 900 mg | 12 days | 9 |
| Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers 2001 · 600 mg WS 5570 · 12 physically and mentally healthy male volunteers | 600 mg | 1 day | — |
| Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin 2004 · Low-dose Hypericum powder, 0.5 g · Healthy volunteers | 500 mg | 2 weeks | — |
| Effects of Hypericum extract (LI160) on the change of auditory evoked potentials by cortisol administration 2004 · LI160 · 19 healthy subjects; age and sex not reported | 600 mg | 2 weeks | — |
| Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction 2004 · Low-HYF SJW treatment · 10 renal transplant patients taking regular cyclosporine; age and sex not reported | 900 mg | 2 weeks | — |
| Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction 2004 · High-HYF SJW treatment · 10 renal transplant patients taking regular cyclosporine; age and sex not reported | 900 mg | 2 weeks | — |
| Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity 2010 · coadministration of ritonavir and St John's wort · Adults; sex and health condition not specified | 900 mg | 2 weeks | — |
| St Johns wort increases expression of P-glycoprotein: implications for drug interactions 2002 · SJW · Healthy volunteers | 1.8 g | 16 days | 15 |
| Oral bioavailability of active principles from herbal products in humans. A study on Hypericum perforatum extracts using the soft gelatin capsule technology 2000 · Soft gelatin formulation · 12 healthy adults, six males and six females | 300 mg | 1 day | 12 |
| Oral bioavailability of active principles from herbal products in humans. A study on Hypericum perforatum extracts using the soft gelatin capsule technology 2000 · Hard gelatin capsule formulation · 12 healthy adults, six males and six females | 300 mg | 1 day | 12 |
| Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers 2001 · 300 mg WS 5570 · 12 physically and mentally healthy male volunteers | 300 mg | 1 day | — |
| Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin 2004 · Low-dose Hypericum powder, 1 g · Healthy volunteers | 1 g | 2 weeks | — |
| Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin 2004 · 2 g Hypericum powder without hyperforin · Healthy volunteers | 2 g | 2 weeks | — |
| Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin 2004 · 4 g Hypericum powder with comparable hyperforin content · Healthy volunteers | 4 g | 2 weeks | — |
| Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin 2004 · 2 g Hypericum powder with half the hyperforin content · Healthy volunteers | 2 g | 2 weeks | — |
| The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose 2006 · LI 160 · Healthy adult men | 41 mg | 2 weeks | — |
| The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose 2006 · SJW powder tablets, HYF 12 mg/day · Healthy adult men | 2.7 g | 2 weeks | — |
| The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose 2006 · SJW powder tablets almost devoid of HYF · Healthy adult men | 2.7 g | 2 weeks | — |
| Early effect of NEURAPAS® balance on current source density (CSD) of human EEG 2011 · NEURAPAS® balance (verum) · Healthy adult volunteers, 8 men and 8 women, mean ages about 47–49 years | 60 mg | 1 day | 16 |
| The effects of St John's wort extract on heart rate variability, cognitive function and quantitative EEG: a comparison with amitriptyline and placebo in healthy men 2002 · St John's wort extract · Healthy men; age not reported | 765 mg | 2 weeks | 12 |